House bill excludes clinical trial compensation from federal taxable income
June 26, 2025
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently in_committee. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →The Frame
If enacted, this measure would prevent clinical trial participants from owing federal income tax on their research compensation, potentially increasing the net financial benefit for volunteers in medical studies.
Potentially affected actors named in the source documents. Mention is not a position.
clinical trial participants
These individuals would no longer be required to report compensation from clinical trials as taxable gross income.
House Committee on Ways and Means
This committee is responsible for reviewing and deciding whether to advance the legislation.
Current stage: in_committee.
Floor Vote.
Summary
Why It Matters
If enacted, this measure would prevent clinical trial participants from owing federal income tax on their research compensation, potentially increasing the net financial benefit for volunteers in medical studies.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
Will I have to pay taxes on money I earn from a clinical trial if this bill passes?
What is the current status of this bill?
News Coverage
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Tax treatment of research participation
The bill signals a legislative effort to incentivize clinical trial participation by removing tax-related financial barriers for volunteers.
Connected Entities
Analysis Score
0–100- Significance45How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools